These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 35139981)

  • 1. Identification of early symptoms and changes in QoL and functioning among men with primary localized prostate cancer who later develop metastases: A matched, prospective study.
    Doveson SE; Holm M; Fransson P; Wennman-Larsen A
    Palliat Support Care; 2022 Feb; ():1-9. PubMed ID: 35139981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
    Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
    Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life in men with metastatic prostate cancer in their final years before death - a retrospective analysis of prospective data.
    Holm M; Doveson S; Lindqvist O; Wennman-Larsen A; Fransson P
    BMC Palliat Care; 2018 Dec; 17(1):126. PubMed ID: 30509249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recall of pretreatment symptoms among men treated with radiotherapy for prostate cancer.
    Fransson P
    Acta Oncol; 2005; 44(4):355-61. PubMed ID: 16120544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
    Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
    Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal changes of health-related quality of life over 10 years in breast cancer patients treated with radiotherapy following breast-conserving surgery.
    Gao Y; Rosas JC; Fink H; Behrens S; Chang-Claude J; Seibold P
    Qual Life Res; 2023 Sep; 32(9):2639-2652. PubMed ID: 37093543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy.
    Lilleby W; Fosså SD; Waehre HR; Olsen DR
    Int J Radiat Oncol Biol Phys; 1999 Mar; 43(4):735-43. PubMed ID: 10098428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: results from the Scandinavian Prostate Cancer Group Study 5.
    Jønler M; Nielsen OS; Groenvold M; Hedlund PO; Damber L; Hedelin H; Waldén M;
    Scand J Urol Nephrol; 2005; 39(1):42-8. PubMed ID: 15764270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
    Tombal B; Saad F; Penson D; Hussain M; Sternberg CN; Morlock R; Ramaswamy K; Ivanescu C; Attard G
    Lancet Oncol; 2019 Apr; 20(4):556-569. PubMed ID: 30770294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life in responders after palliative radiation therapy for painful bone metastases using EORTC QLQ-C30 and EORTC QLQ-BM22: results of a Brazilian cohort.
    Mendez LC; Raman S; Wan BA; da Silva JLP; Moraes FY; Lima KMLB; Silva MF; Diz MDPE; Chow E; Marta GN
    Ann Palliat Med; 2017 Aug; 6(Suppl 1):S65-S70. PubMed ID: 28595442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life in long-term survivors of oropharynx carcinoma.
    Pourel N; Peiffert D; Lartigau E; Desandes E; Luporsi E; Conroy T
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):742-51. PubMed ID: 12377326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
    Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
    Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)ir brachytherapy: a prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25.
    Wahlgren T; Brandberg Y; Häggarth L; Hellström M; Nilsson S
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):51-9. PubMed ID: 15337539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life scores of metastatic pancreatic cancer patients responsive to first line chemotherapy compared to newly derived EORTC QLQ-C30 reference values.
    Amin S; Joo S; Nolte S; Yoo HK; Patel N; Byrnes HF; Costa-Cabral S; Johnson CD
    BMC Cancer; 2022 May; 22(1):563. PubMed ID: 35596182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective evaluation of quality of life 54 months after high-dose intensity-modulated radiotherapy for localized prostate cancer.
    Goineau A; Marchand V; Rigaud J; Bourdin S; Rio E; Campion L; Bonnaud-Antignac A; Mahé MA; Supiot S
    Radiat Oncol; 2013 Mar; 8():53. PubMed ID: 23510499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship of changes in EORTC QLQ-C30 scores to ratings on the Subjective Significance Questionnaire in men with localized prostate cancer.
    Rodrigues G; Bezjak A; Osoba D; Catton P; Tsuji D; Taylor D; Warde P
    Qual Life Res; 2004 Sep; 13(7):1235-46. PubMed ID: 15473502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses.
    Lenz HJ; Argiles G; Yoshino T; Lonardi S; Falcone A; Limón ML; Sobrero A; Hastedt C; Peil B; Voss F; Griebsch I; Van Cutsem E
    Clin Colorectal Cancer; 2019 Dec; 18(4):269-279.e5. PubMed ID: 31628043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported lower urinary tract symptoms, urinary incontinence, and quality of life after external beam radiotherapy for localized prostate cancer--15 years' follow-up. A comparison with age-matched controls.
    Fransson P
    Acta Oncol; 2008; 47(5):852-61. PubMed ID: 17899451
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.